Molbio Collaborates with Niramai Health to Promote Breast Cancer Screening Solution ‘Thermalytix’

Thermalytix is a non-invasive method, which means it doesn’t require any surgical procedures or injections. Additionally, it is a cost-effective, portable, radiation-free test and non-contact solution that measures the temperature of the chest region to detect early-stage breast cancer accurately.

Molbio Diagnostics has collaborated with Niramai Health Analytix, a Bangalore-based deep-tech startup to accelerate the adoption of Niramai's AI-based non-invasive breast cancer screening solution, Thermalytix in developing countries around the world.

Through this collaboration, Molbio will promote and distribute Thermalytix in both public and private healthcare markets globally. The partnership aims to enable efficient screening of large populations, especially in low-resource settings, which is a critical healthcare need across many geographies today.

The screening solution, Thermalytix is a computer-aided, AI-powered diagnostic engine that detects early signs of breast cancer. Further, it uses a high-resolution thermal sensing device and a cloud-hosted analytics solution for analysing thermal images for reliable and accurate breast cancer screening.

Moreover, Thermalytix is a non-invasive method, which means it doesn’t require any surgical procedures or injections. Additionally, it is a cost-effective, portable, radiation-free test and non-contact solution that measures the temperature of the chest region to detect early-stage breast cancer accurately. It is safe, privacy-aware, portable, and enables detection of early-stage malignancy.

Reportedly, clinical trials indicate a high accuracy of Thermalytix that is non-inferior to X-ray mammography in general and offers 25% better sensitivity than mammography in women with dense breasts.

Expressing her views on the collaboration, Dr Geetha Manjunath, founder and CEO, Niramai Health Analytix said, "We are very excited to announce this partnership which has the potential to take our affordable and automated breast screening test to every lady, world over and improve health equity."

As per the World Health Organisation (WHO) report, breast cancer is the most common form of cancer in the world. Although it affects people of all sexes, it impacts women disproportionately, being among the leading causes of death in them and accounting for 24.5% of all new cancer cases in women worldwide.

Founded in 2016, by Geetha Manjunath and Nidhi Mathur, Niramai Health Analytix uses big data analytics and AI over thermal images for early detection of breast cancer.

Whereas, MolbioDiagnostics was founded in 2000, by Sriram Natarajan, Deepak Gurushankar Tripathi and Vinayak Kashinath Naik. It is a manufacturer of research-driven molecular diagnostic products based in Verna, India. The company offers products for diagnosing infectious diseases and also operates a platform that diagnoses infectious diseases including tuberculosis, H1N1 swine flu, dengue, HIV and others.

In August this year, Molbio Diagnostics partnered with CrisprBits, a biotech startup for launching CRISPR-based POC tests. CrisprBits has created a platform for developing POC tests that are quick, accurate, and cost-effective for a variety of diseases and health issues.

This platform has been developed by utilising a specificity of RNA guide-based target identification of nucleic acid and the existence of both cis & trans-cleavage properties of particular Cas enzymes. With this move, the partnership sought to provide cost-effective, innovative, and accurate diagnostic testing.